US4692458A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-hypertensive agents
Assignee: University of Miami
•
Filing: 1980-03-05
•
Granted: 1987-09-08
•
Expires: 2000-03-05
Abstract
Abstract Novel inhibitors of angiotensin converting enzyme having the general formula R--A--S--Z are disclosed as potent inhibitors of angiotensin converting enzyme and are useful anti-hypertensive agents.
Inventors
- 👤 James W. Ryan
- 👤 Alfred Chung
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 00:31
CPC Classifications
C; C07; C07D; C07D403/00; C07D403/02; C07D403/12; A; A61; A61P; A61P43/00; C07C; C07C327/00; C07D207/00; C07D207/02; C07D207/04; C07D207/10; C07D207/16; C07D207/18; C07D207/22; C07D207/46; C07D207/50; C07D211/00; C07D211/04; C07D211/06; C07D211/36; C07D211/60; C07D211/62; C07D211/68; C07D211/72; C07D211/74; C07D211/76; C07D211/80; C07D211/84; C07D211/86; C07D277/00; C07D277/02; C07D277/04; C07D277/06; C07D417/00; C07D417/02; C07D417/12; C07K; C07K5/00; C07K5/04; C07K5/06; C07K5/06086; C07K5/06139; C07K5/06173; C07K5/08; C07K5/0821; A61K; A61K38/00
Claims Analysis
Total Claims: 79
Claim 1
Independent Claim
901 words
A new compound having the general formula I. R--A--S--Z, and the physiologically acceptable salts thereof, wherein: R is selected from hydrogen, formyl, acetyl, propanoyl, butanoyl, phenylacetyl, phenylpropanoyl, benzoyl, cyclopentanecarbonyl, tert-butyloxycarbonyl, cyclopentanecarbonylL-lysyl, pyro-L-glutamyl-L-lysyl, L-arginyl, L-lysyl and pyro-L-glutamyl, A is selected from phenylalanyl, glycyl, alanyl, tryptophyl, tyrosyl, isoleucyl, leucyl, histidyl and valyl and the -amino group of A is in amide linkage with R when R is an acyl group and forms a primary amino group with R when R is hydrogen; S is a sulfur atom joined to A in a thioester linkage; and Z is selected from the following: ##STR60## wherein (i) R 1 and R 1 ' are each hydrogen or halogen, and R 2 and R 3 are each hydrogen, lower alkyl or trifluoromethyl provided that only one of R 2 and R 3 may be trifluoromethyl and further provided that at least one of R 1 , R 1 ', R 2 and R 3 must be halogen or trifluoromethyl; (ii) R 23 is hydrogen or lower alkyl and (iii) m is 0 or 1; ##STR61## wherein (i) R 4 and R 5 are each hydrogen, lower alkyl or phenyl-lower alkylene; (ii) n is 1, 2 or 3; (iii) R 6 is hydrogen or hydroxy or when n is 2, R 6 may also be halogen, and (iv) m and R 23 are as stated in II. above; ##STR62## wherein (i) R 7 is hydrogen, lower alkanoyl or amino (imino)-methyl; (ii) p is 0 or an integer of from 1 to 4; (iii) R 25 is hydrogen but when m is 1, p is 0, R 4 is hydrogen and R 7 is lower alkanoyl, R 25 may also be lower alkyl; (iv) R 8 is selected from hydrogen, lower alkyl and hydroxy lower alkylene when R 9 is selected from hydrogen, lower alkyl, phenyl, phenyl-lower alkylene, hydroxy-lower alkylene, hydroxyphenyl-lower alkylene, amino-lower alkylene, guanidino-lower alkylene, mercapto-lower alkylene, lower alkyl-thio-lower alkylene, imidazolyl-lower alkylene, indolyl-lower alkylene, carbamoyl-lower alkylene and carboxy-lower alkylene but R 8 and R 9 may together constitute a (CH 2 ) v bridge wherein v is 3 or 4, thus forming a 5 or 6-membered ring with the N and C to which R 8 and R 9 are respectively attached and in such instance when v is 3 one hydrogen of (CH 2 ) v may be replaced by OH or halogen and when v is 4, one such hydrogen may be replaced by OH; (v) m and R 23 are each as defined in II. above; and (iv) R 4 is as defined in III. above, provided further, however, that m and p may not both be 0. ##STR63## wherein (i) r 10 is hydrogen or lower alkyl; (ii) R 11 is hydrogen, lower alkyl or lower alkanoyl; (iii) X is 0 or S; (iv) m and R 23 are as stated in II. above, and (v) R 8 , R 9 and p are as stated in IV. above; ##STR64## wherein (i) R 12 is selected from carboxy, lower alkoxycarbonyl, carbamoyl, N-substituted carbamoyl and cyano; (ii) m and R 23 are as stated in II. above; and (iii) R 8 , R 9 and p are as stated in IV. above; ##STR65## wherein (i) R 13 is hydrogen, lower alkyl or phenyl-lower alkylene; (ii) R 14 is selected from hydrogen, lower alkyl, phenyl-lower alkylene, hydroxy-lower alkylene, amino-lower alkylene, guanidino-lower alkylene, imidazolyl-lower alkylene, indolyl-lower alkylene, mercapto-lower alkylene, lower alkyl-thio-lower alkylene, carbamoyl-lower alkylene and carboxy-lower alkylene; (iii) R 4 and R 5 are as stated in III. above; and (iv) q is 0, 1 or 2 ##STR66## wherein (i) R 15 and R 16 are each hydrogen, lower alkyl, phenyl or phenyl-lower alkylene; (ii) r is 0, 1 or 2; (iii) s is 1, 2, or 3; (iv) R 17 is hydrogen, hydroxy or lower alkyl and when s is 2, R 17 may also be halogen; and (v) R 24 is hydroxy, amino or lower alkoxy; provided that when R 24 is OH, s is 2, and R 17 is H or OH: (a) if r is 0, R 16 may not be methyl or H, and (b) if r is 1, R 15 and R 16 may not both be H and R 16 may not be methyl if R 15 is H ##STR67## wherein (i) R 18 is hydrogen or lower alkyl; (ii) R 19 and R 20 are each lower alkyl and may together constitute a (CH 2 ) w bridge wherein w is 4, to form a ring of 5-carbons with the carbon to which they are each attached; (iii) R 21 is hydrogen or lower alkyl and may constitute with R 19 a (CH 2 ) x bridge wherein x is 3, to form a five-membered ring with the N and C to which they are respectively attached; provided, however, that when R 19 and R 21 constitute (CH 2 ) x , R 18 may not be hydrogen or methyl ##STR68## wherein (i) R 22 is hydrogen or lower alkyl; (ii) t and u are each 0 or 1; (iii) R 23 is as stated in II. above; provided, however, that u may not be zero when R 23 is H; and ##STR69## wherein (i) z is 2 or 3; (ii) R 10 is as stated in V. above, and (iii) R 23 is as stated in II above.
Claim 2
Dependent Claim
901 words
A new compound having the general formula I. R--A--S--Z, and the physiologically acceptable salts thereof, wherein: R is selected from hydrogen, formyl, acetyl, propanoyl, butanoyl, phenylacetyl, phenylpropanoyl, benzoyl, cyclopentanecarbonyl, tert-butyloxycarbonyl, cyclopentanecarbonylL-lysyl, pyro-L-glutamyl-L-lysyl, L-arginyl, L-lysyl and pyro-L-glutamyl, A is selected from phenylalanyl, glycyl, alanyl, tryptophyl, tyrosyl, isoleucyl, leucyl, histidyl and valyl and the -amino group of A is in amide linkage with R when R is an acyl group and forms a primary amino group with R when R is hydrogen; S is a sulfur atom joined to A in a thioester linkage; and Z is selected from the following: ##STR60## wherein (i) R 1 and R 1 ' are each hydrogen or halogen, and R 2 and R 3 are each hydrogen, lower alkyl or trifluoromethyl provided that only one of R 2 and R 3 may be trifluoromethyl and further provided that at least one of R 1 , R 1 ', R 2 and R 3 must be halogen or trifluoromethyl; (ii) R 23 is hydrogen or lower alkyl and (iii) m is 0 or 1; ##STR61## wherein (i) R 4 and R 5 are each hydrogen, lower alkyl or phenyl-lower alkylene; (ii) n is 1, 2 or 3; (iii) R 6 is hydrogen or hydroxy or when n is 2, R 6 may also be halogen, and (iv) m and R 23 are as stated in II. above; ##STR62## wherein (i) R 7 is hydrogen, lower alkanoyl or amino (imino)-methyl; (ii) p is 0 or an integer of from 1 to 4; (iii) R 25 is hydrogen but when m is 1, p is 0, R 4 is hydrogen and R 7 is lower alkanoyl, R 25 may also be lower alkyl; (iv) R 8 is selected from hydrogen, lower alkyl and hydroxy lower alkylene when R 9 is selected from hydrogen, lower alkyl, phenyl, phenyl-lower alkylene, hydroxy-lower alkylene, hydroxyphenyl-lower alkylene, amino-lower alkylene, guanidino-lower alkylene, mercapto-lower alkylene, lower alkyl-thio-lower alkylene, imidazolyl-lower alkylene, indolyl-lower alkylene, carbamoyl-lower alkylene and carboxy-lower alkylene but R 8 and R 9 may together constitute a (CH 2 ) v bridge wherein v is 3 or 4, thus forming a 5 or 6-membered ring with the N and C to which R 8 and R 9 are respectively attached and in such instance when v is 3 one hydrogen of (CH 2 ) v may be replaced by OH or halogen and when v is 4, one such hydrogen may be replaced by OH; (v) m and R 23 are each as defined in II. above; and (iv) R 4 is as defined in III. above, provided further, however, that m and p may not both be 0. ##STR63## wherein (i) r 10 is hydrogen or lower alkyl; (ii) R 11 is hydrogen, lower alkyl or lower alkanoyl; (iii) X is 0 or S; (iv) m and R 23 are as stated in II. above, and (v) R 8 , R 9 and p are as stated in IV. above; ##STR64## wherein (i) R 12 is selected from carboxy, lower alkoxycarbonyl, carbamoyl, N-substituted carbamoyl and cyano; (ii) m and R 23 are as stated in II. above; and (iii) R 8 , R 9 and p are as stated in IV. above; ##STR65## wherein (i) R 13 is hydrogen, lower alkyl or phenyl-lower alkylene; (ii) R 14 is selected from hydrogen, lower alkyl, phenyl-lower alkylene, hydroxy-lower alkylene, amino-lower alkylene, guanidino-lower alkylene, imidazolyl-lower alkylene, indolyl-lower alkylene, mercapto-lower alkylene, lower alkyl-thio-lower alkylene, carbamoyl-lower alkylene and carboxy-lower alkylene; (iii) R 4 and R 5 are as stated in III. above; and (iv) q is 0, 1 or 2 ##STR66## wherein (i) R 15 and R 16 are each hydrogen, lower alkyl, phenyl or phenyl-lower alkylene; (ii) r is 0, 1 or 2; (iii) s is 1, 2, or 3; (iv) R 17 is hydrogen, hydroxy or lower alkyl and when s is 2, R 17 may also be halogen; and (v) R 24 is hydroxy, amino or lower alkoxy; provided that when R 24 is OH, s is 2, and R 17 is H or OH: (a) if r is 0, R 16 may not be methyl or H, and (b) if r is 1, R 15 and R 16 may not both be H and R 16 may not be methyl if R 15 is H ##STR67## wherein (i) R 18 is hydrogen or lower alkyl; (ii) R 19 and R 20 are each lower alkyl and may together constitute a (CH 2 ) w bridge wherein w is 4, to form a ring of 5-carbons with the carbon to which they are each attached; (iii) R 21 is hydrogen or lower alkyl and may constitute with R 19 a (CH 2 ) x bridge wherein x is 3, to form a five-membered ring with the N and C to which they are respectively attached; provided, however, that when R 19 and R 21 constitute (CH 2 ) x , R 18 may not be hydrogen or methyl ##STR68## wherein (i) R 22 is hydrogen or lower alkyl; (ii) t and u are each 0 or 1; (iii) R 23 is as stated in II. above; provided, however, that u may not be zero when R 23 is H; and ##STR69## wherein (i) z is 2 or 3; (ii) R 10 is as stated in V. above, and (iii) R 23 is as stated in II above.
Claim 3
Dependent Claim
12 words
The compound of claim 1 wherein A is glycyl, phenylalanyl or tryptophyl.
Claim 4
Dependent Claim
16 words
The compound of claim 1 wherein R is hydrogen, acetyl, benzoyl, cyclopentanecarbonyl, tert-butyloxycarbonyl, cyclopentanecarbonyl-L-lysyl or pyro-L-glutamyl.
Claim 5
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula II.
Claim 6
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula III.
Claim 7
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula IV.
Claim 8
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula V.
Claim 9
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula VI.
Claim 10
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula VII.
Claim 11
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula VIII.
Claim 12
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula IX.
Claim 13
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula X.
Claim 14
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula XI.
Claim 15
Dependent Claim
9 words
The compound of claim 5 wherein n is 2.
Claim 16
Dependent Claim
53 words
The compound of claim 6, 7 or 8 wherein R 8 and R 9 together form a --CH 2 CH 2 CH 2 -- bridge which completes a ring of 5 atoms with the nitrogen and carbon to which they are attached, one carbon optionally bearing a hydroxy group or a halogen group.
Claim 17
Dependent Claim
9 words
The compound of claim 10 wherein s is 2.
Claim 18
Dependent Claim
39 words
The compound of claim 11 wherein R 19 and R 21 together form a --CH 2 CH 2 CH 2 -- bridge which completes a ring of 5 atoms with the nitrogen and carbon to which they are attached.
Claim 19
Dependent Claim
9 words
The compound of claim 12 wherein u is 0.
Claim 20
Dependent Claim
9 words
The compound of claim 13 wherein z is 2.
Claim 21
Dependent Claim
16 words
The compound of claim 1, 4 or 9 wherein R is benzoyl and A is phenylalanyl.
Claim 22
Dependent Claim
15 words
The compound of claim 5 or 14 wherein R is benzoyl and A is phenylalanyl.
Claim 23
Dependent Claim
17 words
The compound of claim 6, 7, 8 or 15 wherein R is benzoyl and A is phenylalanyl.
Claim 24
Dependent Claim
15 words
The compound of claim 10 or 16 wherein R is benzoyl and A is phenylalanyl.
Claim 25
Dependent Claim
15 words
The compound of claim 11 or 17 wherein R is benzoyl and A is phenylalanyl.
Claim 26
Dependent Claim
15 words
The compound of claim 12 or 18 wherein R is benzoyl and A is phenylalanyl.
Claim 27
Dependent Claim
15 words
The compound of claim 13 or 19 wherein R is benzoyl and A is phenylalanyl.
Claim 28
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 1.
Claim 29
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 2.
Claim 30
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 3.
Claim 31
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 4.
Claim 32
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 5.
Claim 33
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 6.
Claim 34
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 7.
Claim 35
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 8.
Claim 36
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 9.
Claim 37
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 10.
Claim 38
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 11.
Claim 39
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 12.
Claim 40
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 13.
Claim 41
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 14.
Claim 42
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 15.
Claim 43
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 16.
Claim 44
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 17.
Claim 45
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 18.
Claim 46
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 19.
Claim 47
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 20.
Claim 48
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 21.
Claim 49
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 22.
Claim 50
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 23.
Claim 51
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 24.
Claim 52
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 25.
Claim 53
Dependent Claim
29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 26.
Claim 54
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 1.
Claim 55
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 2.
Claim 56
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 3.
Claim 57
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 4.
Claim 58
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 5.
Claim 59
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 6.
Claim 60
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 7.
Claim 61
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 8.
Claim 62
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 9.
Claim 63
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 10.
Claim 64
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 11.
Claim 65
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 12.
Claim 66
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 13.
Claim 67
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 14.
Claim 68
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 15.
Claim 69
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 16.
Claim 70
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 17.
Claim 71
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 18.
Claim 72
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 19.
Claim 73
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 20.
Claim 74
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 21.
Claim 75
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 22.
Claim 76
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 23.
Claim 77
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 24.
Claim 78
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 25.
Claim 79
Dependent Claim
28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 26.
References Cited (Backward Citations)
US3865934A
Cited
DE2457463A1
Cited
US3976770A
Cited
US3973006A
Cited
DE2703828A1
Cited
US4140786A
Cited
US4199512A
Cited
US4173704A
Cited
US4140797A
Cited
US4112119A
Cited
US4339600A
Cited
US4206121A
Cited
US4154736A
Cited
US4154936A
Cited
US4127729A
Cited
US4237134A
Cited
US4198517A
Cited
US4140864A
Cited
US4237129A
Cited
US4128721A
Cited
US4175199A
Cited
US4192878A
Cited
US4176235A
Cited
US4165320A
Cited
US4284780A
Cited
US4177277A
Cited
US4154960A
Cited
US4284779A
Cited
US4156786A
Cited
US4154946A
Cited
US4179434A
Cited
US4176291A
Cited
US4154942A
Cited
US4156084A
Cited
US4241076A
Cited
US4206137A
Cited
US4282235A
Cited
US4198509A
Cited
US4483861A
Cited
US4192945A
Cited
US4225495A
Cited
US4198515A
Cited
US4217458A
Cited
US4217359A
Cited
US4252943A
Cited
US4186268A
Cited
US4220791A
Cited
US4211786A
Cited
US4216209A
Cited
US4297275A
Cited
US4235885A
Cited
US4234489A
Cited
US4221912A
Cited
US4221804A
Cited
US4291040A
Cited
US4254267A
Cited
US4284561A
Cited
US4296113A
Cited
US4321392A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-09-07 | 1991-03-09 | 1991-09-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-09-07 | 1995-03-09 | 1995-09-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-09-07 | 1999-03-09 | 1999-09-08 | $7700.00 | Window Closed / Lapsed |